News

Investor's Business Daily on MSN4d
The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent' For Gene Therapies.
Sarepta stock plunged again Thursday on a report that the Food and Drug Administration will require additional clinical ...
PharmExec5d
Recapping the Sarepta Saga—And Implications for Industry
A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...
Fierce Biotech12d
Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning
Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...
MedCity News11mon
Sarepta Gene Therapy Misses in Phase 3; Prospects Now Rely on FDA ...
Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy fell short of its main Phase 3 goal, but the firm contends the full body of evidence supports expanding the therapy’s label to ...
Sarepta drops as report suggests FDA needs new trials for Elevidys
Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its ...
FierceBiotech2y
FDA questions benefits, risks of Sarepta DMD gene therapy - Fierce Biotech
Sarepta says that the risk of patients dropping out once SRP-9001 reaches the market is “extremely low” because there are 45 patients in the trial outside the U.S., which will be the only ...